Abstract: Disclosed herein are high Tm RNA nanostructures that can be composed of one or more modules or motifs to build RNA nanostructures with or without layers. The RNA nanostructures can have a core domain and three or more double-stranded arms and formulations thereof to conjugate high copy numbers of therapeutics, pH responsive or enzyme cleavable drug cargo. Also described herein is a design strategy for generation of synthetic RNA oligonucleotides that can self assemble into highly thermostable RNA structures. Also described herein are uses of the RNA nanostructures described herein.

Abstract: A transmission method includes creating an automatic repeat request process for a first packet; setting a lifetime for the automatic repeat request process; and sending the first packet; and when a preset retransmission condition in the lifetime of the automatic repeat request process is satisfied, retransmitting a second packet; where the preset retransmission condition includes that at least part of the time instants within the first predetermined time interval after an incorrect-reception acknowledgement frame returned by the receiver is received is beyond the lifetime of the automatic repeat request; where retransmitting the second packet includes: extending the lifetime of the automatic repeat request process to a third predetermined time interval following the first predetermined time interval, where the third predetermined time interval is at least a time period required for retransmitting the second packet; and retransmitting the second packet after the first predetermined time interval.

Abstract: A career aspiration-based educational method and system. The educational method includes: according to the user information, determining and recommending an ideal occupational role for the user to select a target occupational role (S102); searching in a ability and knowledge system library of career roles so as to determine a ability and knowledge system required for the target career role, and pre-establishing a ability and knowledge system library of the career role by means of collecting occupational qualification data (S104); customizing a personalized course system for the user according to the capability and knowledge system required for the target occupational role (S106); and providing the teaching of a corresponding course to the user according to the personalized course system (S108).

Abstract: The present invention discloses a highly reliable implantable device of an implantable biological sensor. Before use, the fixed seat cannot move relative to the slidable seat, achieving reliable transportation. In use, the lower end face of the slidable seat is pressed against the skin; the lower end face of the first snap-fit protrusion squeezes the upper end face of the vertical snap-fit plate; the first snap-fit protrusion is gradually away from the support of the vertical snap-fit plate, whereby the inside vertical face of the vertical snap-fit plate pushes the first snap-fit protrusion inward, and the fixed seat moves downward relative to the slidable seat, achieving good controllability.

Abstract: A modified immune effector cell may be one in which the functions of a T cell antigen receptor (TCR) and major histocompatibility complexes (MHCI, MHCII) in the modified immune effector cell are inhibited in a T cell. Such a modified immune effector cell may include a chimeric antigen receptor (CAR) targeting GD2. Such a modified immune effector cell may knock out TCR and HLA-A genes expressed by the cell while recognizing surface antigens of tumor cells, so that multiple effects of improving the anti-tumor effect of CAR-T cells, prolonging the survival time of the cells, and reducing the immune rejection response caused by allogeneic cell therapy may be reduced.

Abstract: Embodiments of this application disclose a direct current offset current cancellation circuit and method, and a related device. An optical detection module included in the cancellation circuit in this application is configured to output a current signal. A first amplification module is configured to convert and amplify the current signal into a voltage signal. A first filtering module is configured to filter the voltage signal to obtain a direct current offset voltage. An acceleration module is configured to provide a target voltage for a charging module. The charging module is configured to output a cancellation voltage based on the target voltage and the direct current offset voltage. A direct current cancellation module is configured to cancel a direct current offset current in the current signal based on the cancellation voltage.

Abstract: Embodiments of this application disclose a trans-impedance amplifier and a trans-impedance amplifier control method that are used in the field of circuit technologies. A trans-impedance amplifier TIA includes an inverting amplification circuit and a voltage clamping circuit. The inverting amplification circuit is connected in parallel to the voltage clamping circuit. The inverting amplification circuit includes a first PMOS transistor and a first NMOS transistor that have a common gate. A source of the first PMOS transistor is connected to a drain of the first NMOS transistor. The voltage clamping circuit includes a second PMOS transistor and a second NMOS transistor that have a common gate. Gates of the two transistors are connected to an input end of the TIA. A source of the second NMOS transistor and a drain of the second PMOS transistor are connected to an output end of the TIA.

Abstract: Apparatuses include (among other components) a first gain device connected to receive an initial voltage, a second gain device in series with the first gain device and connected to receive output of the first gain device, differential gain devices connected to receive outputs from the first gain device and the second gain device (the differential gain devices provide opposite voltage outputs from the apparatus) and high-frequency compensation feed-forward paths connected to the first gain device and the second gain device.

Abstract: A heart valve prosthesis device includes a stent and leaflets. The stent includes an annular part and guide parts. A first end of the annular part includes cell sections arranged in sequence in a circumferential direction of the annular part. The guide parts are arranged at intervals in the circumferential direction of the annular part, one side of each guide part is connected to a corresponding cell section, and the other side gradually tapers to an end where a retrieval cell is provided for a pulling wire to pass through. Each guide part includes a first region being the retrieval cell, a second region aligned with the first region and configured as a central region, and a third region and a fourth region distributed on two sides of the central region in the circumferential direction of the annular part.

Abstract: A titanium dioxide micro-nanocontainers, corrosion-resistant waterborne epoxy coatings and preparation method thereof, including preparation steps as follows: TiO2 micro-nano spheres are synthesized by applying hydrothermal method; a polyaniline layer doped with molybdate ions is deposited on the surface of TiO2 micro-nano spheres by adopting the method of in-situ chemical polymerization, TiO2/PANI-MoO42? micro-nano-spheres are obtained, then, polydopamine is encapsulated on the surface of TiO2/PANI-MoO42? micro-nano spheres to obtain titanium dioxide micro-nanocontainers; next, antirust filler, defoamer, dispersant and thickener are added into waterborne epoxy emulsion, then titanium dioxide micro-nanocontainers are added in the waterborne epoxy emulsion for dispersing and grinding, filtering and encapsulating to obtain component A; the waterborne epoxy curing agent and deionized water are mixed in proportion to obtain component B; component A is stirred, then it is mixed with the component B in proportion,

Abstract: The present disclosure provides use of Clostridium ghonii combined with a tumor angiogenesis inhibitor in preparing a pharmaceutical product for treating a tumor. The present disclosure further provides a drug for treating a tumor, where the drug includes active ingredients of Clostridium ghonii and a tumor angiogenesis inhibitor.

Abstract: A computer-implemented method of processing digital image data. The method includes: determining, by an encoder configured to map a first digital image to an extended latent space associated with a generator of a generative adversarial network, GAN, system, a noise prediction associated with the first digital image, determining, by the generator of the GAN system, at least one further digital image based on the noise prediction associated with the first digital image and a plurality of latent variables associated with the extended latent space.

Abstract: A computer-implemented method for training an encoder. The encoder is configured for determining a latent representation of an image. Training the encoder includes: determining a latent representation and a noise image by providing a training image to the encoder, wherein the encoder is configured for determining a latent representation and a noise image for a provided image; masking out parts of the noise image, thereby determining a masked noise image; determining a predicted image by providing the latent representation and the masked noise image to a generator of a generative adversarial network; training the encoder by adapting parameters of the encoder based on a loss value, wherein the loss value characterizes a difference between the predicted image and the training image.

Abstract: Various embodiments of the teachings herein include a method for deploying power quality monitoring (PQM) devices. The method may include: determining a maximum number of PQM devices and historical power data of candidate deployment points, wherein the number of the candidate deployment points is greater than the maximum number of the PQM devices; clustering the historical power data of the candidate deployment points, wherein a target number of categories is determined on the basis of a silhouette coefficient of each candidate number of categories and the maximum number of the PQM devices; and determining PQM device deployment points based on the center of each category in the target number of categories.

Abstract: A nonlinear radar system includes a first antenna configured to generate and emit an incident signal having a first frequency, a transponder tag attached to an existing portable object, wherein the transponder tag includes an electromagnetic nonlinear element configured to be detected by the incident signal. Upon being detected by the incident signal, the transponder tag is configured to transmit a reflected return harmonic signal having a second frequency different from the first frequency, wherein the reflected return harmonic signal is an on-off keying (OOK) signal. A second antenna is configured to receive the reflected return harmonic signal having the second frequency. The transponder tag includes a conductive layer in electrical communication with the electromagnetic nonlinear element including a Schottky diode.

Abstract: The present disclosure relates to an injectable lurasidone suspension and a preparation method thereof, and in particular to an irregular form of a lurasidone solid and a pharmaceutical composition thereof. The present disclosure also relates to a preparation method for the solid and the pharmaceutical composition thereof, and an application thereof in the treatment of mental diseases. According to the present disclosure, the lurasidone solid prepared has controllable particle size and has Dv5O particle size of 6 ?m to 110 ?m. The good particle size stability can also he maintained in the pharmaceutical composition. The lurasidone suspension preparation obtained by the method is fast-acting, has a long sustained release period, and can effectively reduce the risk caused by poor patient compliance.

Abstract: The present application discloses a recombinant Newcastle disease virus genome, a recombinant Newcastle disease virus rNDV-VEGF-Trap containing the genome and a preparation method therefor, a DNA molecule encoding the recombinant Newcastle disease virus genome, and a use of the genome and the recombinant Newcastle disease virus in the preparation of a drug for treating cancer. The recombinant Newcastle disease virus provided by the present application relates to inserting a coding gene of VEGF-Trap into the genome of the recombinant Newcastle disease virus, such that the recombinant Newcastle disease virus obtained therefrom is replicated with a strong replication capability, thereby killing host cancer cells; moreover, the recombinant Newcastle disease virus has reliable safety for non-cancer cells, and shows improved anti-tumor effect and oncolytic efficiency.

Abstract: Method of inhibiting a protein-protein interaction between Von Hippel-Lindau tumor-suppressor protein and hypoxia-inducible factor 1-alpha useful in the treatment of angiogenesis-related diseases and promoting wound healing.

Abstract: An application of a hydrogel in the preparation of products for the treatment of bacterial infection is disclosed. Ferrous ion was used in the antibacterial activity test of Staphylococcus aureus and showed a strong bactericidal effect, which the survival rate of Staphylococcus aureus is less than 0.001%, as well as the survival rate of methicillin-resistant Staphylococcus aureus (MRSA) was less than 0.01%. Ferrous ion hydrogel was used for the treatment of keratitis and skin wound infection. Ferrous ion hydrogel for the treatment of keratitis and skin wound infection, which can significantly reduce the risk of pulmonary MRSA infection, prevented the dissimilation of MRSA to the lung, and alleviated systemic inflammation in the body in a timely and effective manner, revealing the therapeutic potential of ferrous compounds for treatment of Staphylococcus aureus infections, including MRSA.

Abstract: The present disclosure relates to use of a Clostridium ghonii spore combined with pembrolizumab in cancer treatment. It is found for the first time that the Clostridium ghonii spore combined with pembrolizumab can significantly improve a curative effect of colon cancer and reduce a dose of the pembrolizumab, and thus is efficient and low-toxic. Oncolysis by Clostridium ghonii can affect immunogenicity of a tumor microenvironment (TME) by various ways, converts an immunosuppressive state of the TME into an immune-activated state, adjusts the immunosuppressive TME, and breaks an immune tolerance. An optimal combination of the Clostridium ghonii spore and the pembrolizumab thoroughly removes about 20% of mouse tumor tissues. A benefit range of patients with tumors treated by a PD-1 antibody is expanded. The combination even has an obvious curative effect on patients failed the treatment by the PD-1 antibody.